MedPath

A study on the efficacy of Oral Disintegration Tablet (ODT), a dietary supplement containing polyherbal extracts in the management of Xerostomia in Head and Neck Cancer patients receiving radiation treatment

Phase 2
Conditions
Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
Registration Number
CTRI/2022/11/047416
Lead Sponsor
Dr Harikrishnan MD Ayu
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. ECOG Performance status I and II

2. Patients treated with two opposing lateral fields

including parotid using 2D technique

3. Patients undergoing radiation or chemoradiation

Exclusion Criteria

1. Lymphoma histology

2. Patients undergoing re irradiation

3. Patients with comorbidities

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To analyse the change in the Clinical Oral Dryness Score from the baseline at the time of final assessmentTimepoint: base line, completion of treatment, 3 months follow up and 6 months follow up
Secondary Outcome Measures
NameTimeMethod
To assess whether the subjective scoring [Xerostomia Inventory score] is <br/ ><br>correlating with the objective Clinical Oral Dryness Score <br/ ><br>Timepoint: base line, completion of treatment, 3 months follow up and 6 months follow up
© Copyright 2025. All Rights Reserved by MedPath